drugset / Trial / NCT04305457
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19
Phase 2
Terminated
62 enrolled
Massachusetts General Hospital
University of Alabama at Birmingham · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (SARS-Cov-2) originated in China in December 2019. At present, there are no proven interventions to prevent progression of the disease. Some preliminary data on SARS pneumonia suggest that inhaled Nitric Oxide (NO) could have beneficial effects on SARS-CoV-2 due to the genomic similarities between this two coronaviruses. In this study we will test whether inhaled NO therapy prevents progression in patients with mild to moderate COVID-19 disease.
Timeline
- Start
- 2020-03-21
- Primary completion
- 2023-08-23
- Completion
- 2023-08-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nitric Oxide | Other / unclassified | 140 ppm | Inhaled |
| Subject | Nitric Oxide | Other / unclassified | 180 ppm | Inhaled |